Physician profile
Jodi M Wilhelm
NPI 1205278702
$5,006.11
in general payments reported to CMS, 2019-2025
24 companies · $861 in 2025
The $861 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,097 · 2022: $1,195 · 2023: $1,044 · 2024: $810 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,714.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,302.51 | 2021-2025 | |
| Pfizer INC. | $468.61 | 2021-2025 | |
| Allergan, INC. | $392.59 | 2021-2022 | |
| Galderma Laboratories, L.P. | $248.82 | 2021-2022 | |
| Amgen INC. | $192.12 | 2021-2025 | Evenity, Prolia |
| Biohaven Pharmaceutical Holding Company LTD. | $180.73 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $149.44 | 2021 | |
| Merz Pharmaceuticals, LLC | $139.22 | 2021-2024 | Xeomin |
| Upsher-Smith Laboratories LLC | $134.43 | 2021-2023 | |
| Lilly USA, LLC | $129.39 | 2021-2024 | Emgality, Reyvow |
| Lundbeck LLC | $111.59 | 2024-2025 | Vyepti |
| Novo Nordisk INC | $82.57 | 2022-2025 | Wegovy |
| Axsome Therapeutics, INC. | $79.74 | 2024-2025 | Sunosi, Symbravo |
| Ipsen Biopharmaceuticals, INC | $77.88 | 2023-2024 | Dysport |
| Merz North America, INC. | $54.68 | 2022-2023 | Xeomin |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $54.03 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $43.16 | 2025 | |
| Abiomed | $39.04 | 2023 | Impella |
| Shield Therapeutics INC | $32.11 | 2025 | |
| Arbor Pharmaceuticals, INC. | $24.54 | 2021 | |
| Bioventus LLC | $19.90 | 2024 | Durolane |
| Impel Pharmaceuticals INC. | $17.72 | 2023 | Trudhesa |
| Xeris Pharmaceuticals, INC. | $15.79 | 2025 | Recorlev |
| Currax Pharmaceuticals LLC | $15.50 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodi Wilhelm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.